Legend Operating Cycle from 2010 to 2026

LEGN Stock  USD 17.58  0.48  2.66%   
Legend Biotech Operating Cycle yearly trend continues to be very stable with very little volatility. Operating Cycle is likely to drop to 120.03. During the period from 2010 to 2026, Legend Biotech Operating Cycle quarterly data regression pattern had sample variance of 2.8 M and median of  806.53. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
126.35
Current Value
120.03
Quarterly Volatility
1.7 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Legend Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Legend Biotech's main balance sheet or income statement drivers, such as Tax Provision of 22.8 M, Depreciation And Amortization of 28.2 M or Interest Expense of 26.1 M, as well as many indicators such as Price To Sales Ratio of 5.18, Dividend Yield of 0.0 or PTB Ratio of 3.12. Legend financial statements analysis is a perfect complement when working with Legend Biotech Valuation or Volatility modules.
  
Build AI portfolio with Legend Stock
Check out the analysis of Legend Biotech Correlation against competitors.
Evaluating Legend Biotech's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Legend Biotech Corp's fundamental strength.

Latest Legend Biotech's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Legend Biotech Corp over the last few years. It is Legend Biotech's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Legend Biotech's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Legend Operating Cycle Regression Statistics

Arithmetic Mean1,795
Geometric Mean826.25
Coefficient Of Variation92.58
Mean Deviation1,602
Median806.53
Standard Deviation1,662
Sample Variance2.8M
Range3.4K
R-Value(0.89)
Mean Square Error615,298
R-Squared0.79
Slope(292.64)
Total Sum of Squares44.2M

Legend Operating Cycle History

2026 120.03
2025 126.35
2024 109.87
2023 250.23
2022 196.68
2021 310.49
2020 402.06

About Legend Biotech Financial Statements

Legend Biotech investors utilize fundamental indicators, such as Operating Cycle, to predict how Legend Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cycle 126.35  120.03 

Pair Trading with Legend Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Legend Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Legend Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving together with Legend Stock

  0.82OSE OSE Pharma SAPairCorr

Moving against Legend Stock

  0.84DRTS Alpha Tau MedicalPairCorr
  0.8EQ EquilliumPairCorr
  0.8DSGN Design TherapeuticsPairCorr
  0.776C1 CytomX TherapeuticsPairCorr
  0.67DNTH Dianthus TherapeuticsPairCorr
The ability to find closely correlated positions to Legend Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Legend Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Legend Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Legend Biotech Corp to buy it.
The correlation of Legend Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Legend Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Legend Biotech Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Legend Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Legend Biotech Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Legend Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Legend Biotech Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Legend Biotech Corp Stock:
Check out the analysis of Legend Biotech Correlation against competitors.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Will Biotechnology sector continue expanding? Could Legend diversify its offerings? Factors like these will boost the valuation of Legend Biotech. Expected growth trajectory for Legend significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Legend Biotech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.28)
Revenue Per Share
4.94
Quarterly Revenue Growth
0.7
Return On Assets
(0.07)
Return On Equity
(0.23)
Investors evaluate Legend Biotech Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Legend Biotech's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Legend Biotech's market price to deviate significantly from intrinsic value.
Understanding that Legend Biotech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Legend Biotech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Legend Biotech's market price signifies the transaction level at which participants voluntarily complete trades.